Book contents
- Case Studies in Neuropalliative Care
- Case Studies in Neuropalliative Care
- Copyright page
- Contents
- Contributors
- Section 1 Palliative Care Principles
- Section 2 Cerebrovascular Diseases
- Section 3 Neurodegenerative and Neuromuscular Diseases
- Section 4 Neuro-oncology
- Section 5 Pediatric Neurology
- Section 6 Demyelinating Diseases and Autoimmune Neurology
- Index
- References
Section 4 - Neuro-oncology
Published online by Cambridge University Press: 08 June 2018
Edited by
Book contents
- Case Studies in Neuropalliative Care
- Case Studies in Neuropalliative Care
- Copyright page
- Contents
- Contributors
- Section 1 Palliative Care Principles
- Section 2 Cerebrovascular Diseases
- Section 3 Neurodegenerative and Neuromuscular Diseases
- Section 4 Neuro-oncology
- Section 5 Pediatric Neurology
- Section 6 Demyelinating Diseases and Autoimmune Neurology
- Index
- References
Summary
A summary is not available for this content so a preview has been provided. Please use the Get access link above for information on how to access this content.
- Type
- Chapter
- Information
- Case Studies in Neuropalliative Care , pp. 113 - 144Publisher: Cambridge University PressPrint publication year: 2018
References
Suggested Reading
Gofton, TE, Graber, J, Carver, A. Identifying the palliative care needs of patients living with cerebral tumors and metastases: a retrospective analysis. Journal of Neuro-oncology. 2012;108(3):527–34.Google Scholar
Flechl, B, Ackerl, M, Sax, C, et al. The caregivers’ perspective on the end-of-life phase of glioblastoma patients. Journal of Neuro-oncology. 2013;112(3):403–11.Google Scholar
Walbert, T, Khan, M. End-of-life symptoms and care in patients with primary malignant brain tumors: A systematic literature review. Journal of Neuro-oncology. 2014;117(2):217–24.Google Scholar
Sizoo, EM, Braam, L, Postma, TJ, et al. Symptoms and problems in the end-of-life phase of high-grade glioma patients. Neuro-oncology. 2010;12(11):1162–6.Google Scholar
Diamond, EL, Panageas, KS, Dallara, A, et al. Frequency and predictors of acute hospitalization before death in patients with glioblastoma. Journal of Pain and Symptom Management. 2017;53(2):257–64.Google Scholar
Diamond, EL, Corner, GW, De Rosa, A, Breitbart, W, Applebaum, AJ. Prognostic awareness and communication of prognostic information in malignant glioma: A systematic review. Journal of Neuro-oncology. 2014;119(2):227–34.Google Scholar
Sizoo, EM, Pasman, HR, Buttolo, J, et al. Decision-making in the end-of-life phase of high-grade glioma patients. European Journal of Cancer (Oxford, England: 1990). 2012;48(2):226–32.Google Scholar
Sizoo, EM, Taphoorn, MJ, Uitdehaag, B, et al. The end-of-life phase of high-grade glioma patients: Dying with dignity? The Oncologist. 2013;18(2):198–203.Google Scholar
Diamond, EL, Russell, D, Kryza-Lacombe, M, et al. Rates and risks for late referral to hospice in patients with primary malignant brain tumors. Neuro-oncology. 2016;18(1):78–86.Google Scholar
Suggested Reading
Omuro, A, Correa, DD, DeAngelis, LM, et al. R-MPV followed by high-dose chemotherapy with TBC and autologous stem-cell transplant for newly diagnosed primary CNS lymphoma. Blood. 2015;125:1403–10.Google Scholar
Albrecht, TA. Symptom clusters in various solid tumors and hematologic malignancies. In Dahlin, C, Coyne, PJ, Ferrell, BR, eds. Advanced Practice Palliative Nursing. New York: Oxford University Press, 2016, 345–56.Google Scholar
Epstein, RM, Entwistle, VS. Capacity and shared decision making in serious illness. In Quill, TE, Miller, FG, eds. Palliative Care and Ethics. New York: Oxford University Press, 2014, 162–86.Google Scholar
Suggested Reading
International Association for the Study of Pain (IASP). Diagnosis and classification of neuropathic pain. 2010. www.iasp-pain.org/PublicationsNews/NewsletterIssue.aspx?ItemNumber=2083. Accessed March 23, 2017.Google Scholar
Bennett, MI, Rayment, C, Hjermstad, M, et al. Prevalence and aetiology of neuropathic pain in cancer patients: A systematic review. Pain. 2011;153:359–65.Google Scholar
Rayment, C, Hjermstad, MJ, Aass, N, et al. Neuropathic cancer pain: Prevalence, severity, analgesics and impact from the European Palliative Care Research Collaborative computerised symptom assessment study. Palliative Medicine. 2012; 27:714–21.Google Scholar
Paice, JA. Pain. In Dahlin, C, Coyne, PJ, Ferrell, BR, eds. Advanced Practice Palliative Nursing. New York: Oxford University Press, 2016, 219–32.Google Scholar
Suggested Reading
International Association for the Study of Pain (IASP). Diagnosis and classification of neuropathic pain. 2010. www.iasp-pain.org/PublicationsNews/NewsletterIssue.aspx?ItemNumber=2083. Accessed March 23, 2017.Google Scholar
Bennett, MI, Rayment, C, Hjermstad, M, et al. Prevalence and aetiology of neuropathic pain in cancer patients: A systematic review. Pain. 2011;153:359–65.Google Scholar
Rayment, C, Hjermstad, MJ, Aass, N, et al. Neuropathic cancer pain: Prevalence, severity, analgesics and impact from the European Palliative Care Research Collaborative computerised symptom assessment study. Palliative Medicine. 2012;27:714–21.Google Scholar
Mols, F, Beijers, T, Vreugdenhil, G, van de Poll-Franse, L. Chemotherapy-induced peripheral neuropathy and its association with quality of life: A systematic review. Support Care Cancer. 2014;22:2261–9.CrossRefGoogle ScholarPubMed
Pachman, DR, Watson, JC, Lustberg, MB, et al. Management options for established chemotherapy-induced peripheral neuropathy. Support Care Cancer. 2014;22:2281–95.Google Scholar
Paice, JA. Pain. In Dahlin, C, Coyne, PJ, Ferrell, BR, eds. Advanced Practice Palliative Nursing. New York: Oxford University Press, 2016, 219–32.Google Scholar
Paice, JA. Pain at the end of life. In Ferrell, BR, Coyle, N, Paice, J, eds. Oxford Textbook of Palliative Nursing, 4th Edition. New York: Oxford University Press. 2015, 135–53.Google Scholar
Suggested Reading
Mandel, JJ, Yust-Katz, S, Cachia, D, Wu, J, Liu, D, de Groot, JF, Yung, AW, Gilbert, MR. Leptomeningeal dissemination in glioblastoma: An inspection of risk factors, treatment, and outcomes at a single institution. J Neurooncol. 2014 Dec;120(3):597–605.Google Scholar
De la Fuente, MI, DeAngelis, LM. The role of ventriculoperitoneal shunting in patients with supratentorial glioma. Ann Clin Transl Neurol. 2014 Jan;1(1):45–8.Google Scholar
Weeks, JC, Catalano, PJ, Cronin, A, Finkelman, MD, Mack, JW, Keating, NL, Schrag, D. Patients’ Expectations about effects of chemotherapy for advanced cancer. N Engl J Med. 2012 Oct;367(17):1616–25.Google Scholar
Diamond, EL, Corner, GW, De Rosa, A, Breitbart, W, Applebaum, AJ. Prognostic awareness and communication of prognostic information in malignant glioma: A systematic review. J Neurooncol. 2014 Sep;119(2):227–34.Google Scholar
Stupp, R, Mason, WP, Van den Bent, MJ, Weller, M, Fisher, B, Taphoorn, MJ, Belanger, K, Brandes, AA, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005 Mar;352(10):987–96.Google Scholar
Davies, E, Clarke, C, Hopkins, A. Malignant cerebral glioma – II: Perspectives of patients and relatives on the value of radiotherapy. BMJ. 1996 Dec;313(7971):1512–16.Google Scholar
Temel, JS, Greer, JA, Muzikansky, A, Gallagher, ER, Admane, S, Jackson, VA, Dahlin, CM, Blinderman, CD, Jacobsen, J, Pirl, WF, Billings, JA, Lynch, TJ. Early palliative care for patients with metastatic non-small-cell lung cancer. N Engl J Med. 2010 Aug;363(8):733–42.Google Scholar
Thomas, A, Carver, A. Essential competencies in palliative medicine for neuro-oncologists. Neuro-oncology Practice. 2015 May;2(3):151–7.Google Scholar
Suggested Reading
Thomas, AA, Carver, A. Essential competencies in palliative medicine for neuro-oncologists. Neuro-Oncology Practice, 2015; 0: 1–7.Google Scholar
Gofton, TE, Graber, J, Carver, A. Identifying the palliative care needs of patients living with cerebral tumors and metastases: A retrospective analysis. J Neurooncol. 2012 July;108(3):527–34.Google Scholar
Pace, A, Villani, V, Di Lorenzo, C, Guariglia, L, Maschio, M, Pompili, A, Carapella, CM. Epilepsy in the end-of-life phase in patients with high-grade gliomas. J NEurooncol. 2013 Jan;111(1):83–6.Google Scholar
Sizoo, EM, Koekkoek, JA, Postma, TJ, Heimans, JJ, Pasman, HR, Deliens, L, Taphoorn, MJ, Rijneveld, JC. Seizures in patients with high-grade glioma: A serious challenge in the end of life. BMJ Support Palliat Care. 2014 Mar;4(1):77–80.Google Scholar
Sizoo, EM, Taphoom, MJ, Uitdehaag, B, Heimans, JJ, Deliens, L, Reijneveld, JC, Pasman, HR. The end-of-life phase of high-grade glioma patients: Dying with dignity? Oncologist. 2013 Jan;18(2):198–203.Google Scholar
Chochinov, HM, Hack, T, Hassard, T, Kristjanson, LJ, McClement, S, Harlos, M. Dignity in the terminally ill: A cross-sectional, cohort study. Lancet. 2002 Dec;360(9350):2026–30.Google Scholar
Carver, AC, Foley, MF. Symptom assessment and management. Neurology Clinics: Palliative Care. Eds. Carver, AC, Foley, KM. Philadelphia, PA: W. B. Saunders, 2001. 940.Google Scholar
Suggested Reading
Walbert, T, Chasteen, K. Palliative and supportive care for glioma patients. Cancer Treat Res. 2015;163:171–84.Google Scholar
Sizoo, EM, Koekkoek, JAF, Postma, TJ, et al. Seizures in patients with high grade glioma: A serious challenge in the end-of-life phase. BMJ Support Palliative Care, 2013; 0:1–4.Google Scholar
Glantz, MJ, Cole, BF, Forsyth, PA, et al. Practice parameter: Anticonvulsant prophylaxis in patients with newly diagnosed brain tumors. Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2000;54:1886–93.Google Scholar
Fritz, L, Dirven, L, Reijneveld, JC, et al. Advance care planning in glioblastoma patients. Cancers. 2016;8:11.Google Scholar
Rémi, C, Zwanzig, V, Feddersen, B. Subcutaneous use of lacosamide. J Pain Symptom Management. 2016;51:e2–4.Google Scholar
Koekkoek, J, Postman, T, Heimans, J, et al. Antiepileptic drug treatment in the end-of-life phase of glioma patients: A feasibility study. Support Care Cancer. 2016; 24:1633–8.Google Scholar
Anderson, GD, Saneto, RP. Current oral and non-oral routes of anti-epileptic drug delivery. Advanced Drug Delivery Rev. 2012;64:911–18.Google Scholar
Rémi, C, Lorenzl, S. Continuous subcutaneous use of levetiracetam: A retrospective review of tolerability and clinical effects. J Pain Palliative Care Pharmacother. 2014;28 (4):371–7.Google Scholar
Lopez-Saca, J, Vaquero, J, Larumbe, A, et al. Repeated use of subcutaneous levetiracetam in a palliative care patient. J Pain Symptom Management. 2013;45 (5): e7–8.CrossRefGoogle Scholar
Jain, P, Sharma, S, Dua, T, et al. Efficacy and safety of anti-epileptic drugs in patients with active convulsive seizures when no IV access is available: Systematic review and meta-analysis. Epilepsy Res. 2016;122: 47–55.Google Scholar
Suggested Reading
Vig, E, Starks, H, Taylor, J, Hopley, E, Fryer, K. Surviving surrogate decision-making: What helps and hampers the experience of making medical decisions for others. J Gen Intern Med. 2007 Sep;22(9):1274–9.Google Scholar
Lin, E, Rosenthal, M, Le, B, Eastman, P. Neuro-oncology and palliative care: A challenging interface. Neuro-oncology. 2012;14:iv3–iv7.Google Scholar
Tanaka, S, Meyer, FB, Buckner, JC, Uhm, JH, Yan, ES, Parney, IF. Presentation, management, and outcome of newly diagnosed glioblastoma in elderly patients. J Neurosurg. 2013;118:786–98.Google Scholar
Stupp, R, Mason, W, Van den Bent, M, Weller, M, Fisher, B, Taphoorn, M, Belanger, K, Brandes, A, Marosi, C, Bogdahn, U, Curschmann, J, Janzer, R, Ludwin, S, Gorlia, T, Allgeier, A, Lacombe, D, Cairncross, G, Eisenhauer, E, Mirimanoff, R. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352: 987–96.Google Scholar
Sanson, M, Marie, Y, Paris, S, Idbaih, A, Laffaire, J, Ducray, F, El Hallani, S, Boisselier, B, Mokhtari, K, Hoang-Xuan, K, Delattre, JY. Isocitrate Dehydrogenase 1 Codon 132 mutation is an important prognostic biomarker in gliomas. J Clin Oncol. 2009;27(25): 4150–4.Google Scholar
Zhang, K, Wang, XQ, Zhou, B, Zhang, L. The prognostic value of MGMT promoter methylation in Glioblastoma multiforme: A meta-analysis. Familial Cancer. 2013;12: 449–58.Google Scholar
Hemminger, LE, Pittman, C, David, NK, and Mohile, NA. Palliative and end-of-life care in glioblastoma: Defining and measuring opportunities to improve care. Neurooncol Pract. 2016;npw022.Google Scholar
Suggested Reading
Quill, TE, Abernethy, AP. Generalist plus specialist palliative care – creating a sustainable model. NENgl J Med. 2013 Mar 28;368(13):1173–5.Google Scholar
Norden, AD, Wen, PY, Kesari, S. Brain metastases. Curr Opin Neurol. 2005;18(6):654–61.Google Scholar
Owonikoko, TK, Arbiser, J, Zelnak, A, Shu, HK, Robin, AM, Kalkanis, SN, Whitsett, TG, Salhia, B, Tran, NL, Ryken, T, Moore, MK, Egan, KM, Olson, JJ. Current approaches to the treatment of metastatic brain tumours. Nature Reviews Clinical Oncology. 2014;11: 203–22.Google Scholar
Davies, MA, Lui, P, McIntyre, S, Kim, KB, Papadopoulos, N, Hwu, WJ, Hwu, P, Bedikian, A. Prognostic factors for survival in melanoma patients with brain metastases. Cancer. 2010;117(8):1687–96.Google Scholar
Mandybur, TI. Intracranial hemorrhage caused by metastatic tumors. Neurology. 1977;27(7):650.Google Scholar
Taillibert, S, Delattre, JY. Palliative care in patients with brain metastases. Curr Opin Oncol. 2005;17(6):588–92.Google Scholar
Suggested Reading
Cohen, SP, Argoff, CE, Carragee, EJ. Management of low back pain. BMJ. 2009;338:100–6.Google Scholar
Gordon, DB, Dahl, JL, Miaskowski, C. American Pain Society recommendations for improving the quality of acute and cancer pain management. Arch Intern Med. 2005;165(14):1574–80.Google Scholar